Financial Decoupling: China Biotechs Brace For Potential US Delistings, Softening Economy
Executive Summary
US-listed Chinese biotechs face a potential double-whammy from US rules requiring accounting transparency at the risk of delisting, while other challenges loom from a general regulatory crackdown and economic softening in China, along with rising COVID-19 cases.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and Scrip Asks what 2022 holds for digital and telehealth.
SEC Puts US-Listed Chinese Biopharma Firms On Notice To Comply With 2020 Law
Chinese companies publicly traded in the US – including BeiGene, HutchMed and Zai Lab – have three years to switch to accounting firms that can be investigated by the US government, or two years if a pending amendment is adopted.
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.